Real-world data on palbociclib combo for breast cancer in japan
NCT ID NCT05399329
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked back at medical records of 693 Japanese patients with a certain type of advanced breast cancer (HR+/HER2-) who received palbociclib plus endocrine therapy as their first or second treatment. Researchers measured how long patients lived without the cancer getting worse and overall survival. The goal is to see how well this treatment works in everyday practice, not just in clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
palbociclib plus endocrine therapy
What this could lead to
If successful, this study could confirm that palbociclib plus endocrine therapy works well in real-world Japanese patients, supporting its continued use.
What could go wrong
This is a retrospective observational study, not a controlled trial, so results may be influenced by patient selection or missing data. It cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Nagoya, 464-8681, Japan
-
Gifu University Hospital
Gifu, 501-1194, Japan
-
Hiroshima University Hospital
Hiroshima, 734-8551, Japan
-
Hokkaido Cancer Center
Sapporo, Hokkaido, 003-0804, Japan
-
Ishikawa Prefectural Central Hospital
Kanazawa, Ishikawa-ken, 920-8530, Japan
-
Japan Community Health care Organization Kurume General Hospital
Kurume, Fukuoka, 830-0013, Japan
-
Jichi Medical University Hospital
Shimotsuke, Tochigi, 329 0498, Japan
-
Kaizuka City Hospital
Kaizuka, Osaka, 597-0015, Japan
-
Kitasato University Hospital
Sagamihara, Kanagawa, 252-0329, Japan
-
Nagoya University Hospital
Nagoya, Aichi-ken, 466-8560, Japan
-
National Hospital Organization Osaka National Hospital
Osaka, 540-0006, Japan
-
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, 791-0280, Japan
-
Osaka International Cancer Institute
Osaka, Osaka, 541-8567, Japan
-
Osaka University Hospital
Suita, Osaka, 565-0871, Japan
-
Saitama Prefectural Cancer Center
Kita-adachi-gun, Saitama, 362-0806, Japan
-
Seirei Hamamatsu General Hospital
Hamamatsu, Shizuoka, 430-8558, Japan
-
Shizuoka Prefectural Hospital Organization
Shizuoka, 420-8527, Japan
-
Showa University Hospital
Tokyo, 142-8666, Japan
-
Tohoku University Hospital
Sendai, Miyagi, 980-8574, Japan
-
Tokai University Hospital
Kanagawa, 259-1193, Japan